Genmab A (GMAB) Revenue (2018 - 2026)

Genmab A (GMAB) posted Revenue of $896.0 million for Q1 2026, down 66.34% on a QoQ basis from $2.7 billion in Q3 2025, and up 25.31% year-over-year from $715.0 million in Q1 2025.

Genmab A (GMAB) Revenue (2018 - 2026) Analysis & Trends

Genmab A's Revenue history runs 6 years deep, the most recent figure standing at $896.0 million for Q1 2026.

  • Quarterly Revenue rose 25.31% year-over-year to $896.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 billion (up 20.72% YoY) and the FY2025 annual result came in at $3.7 billion, up 19.19% from the prior year.
  • Revenue was $896.0 million for Q1 2026 at Genmab A, down from $2.7 billion in the prior quarter.
  • Across five years, Revenue topped out at $2.7 billion in Q3 2025 and bottomed at $603.0 million in Q1 2024.
  • A 3-year average of $1.4 billion and a median of $1.4 billion in 2024 frame the typical range for Revenue.
  • Annual changes were most pronounced in 2025 — Revenue climbed 18.57% — and 2026, when it rose 25.31%.
  • Genmab A's Revenue stood at $2.2 billion in 2024, then grew by 21.11% to $2.7 billion in 2025, then plunged by 66.34% to $896.0 million in 2026.
  • Business Quant data shows GMAB's Revenue at $896.0 million in Q1 2026, $2.7 billion in Q3 2025, and $1.6 billion in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.51 Bn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.56 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Genmab A 1.89 Bn 366.92 Mn 831.00 Mn 896.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 896.00 Mn
Sep 30, 2025 2.66 Bn
Jun 30, 2025 1.64 Bn
Mar 31, 2025 715.00 Mn
Sep 30, 2024 2.20 Bn
Jun 30, 2024 1.38 Bn
Mar 31, 2024 603.00 Mn
Sep 30, 2020 1,724,000.00 Bn
Dec 31, 2019 1,040.00
Sep 30, 2019 0.00
Dec 31, 2018 598.60 Mn